This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.
National Vision (EYE) Hurt by Rising Costs, Vendor Dependency
by Zacks Equity Research
High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.
Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays
by Zacks Equity Research
According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.
Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair
by Zacks Equity Research
Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Encompass Health's (EHC) Nationwide Hospital Count Rises to 147
by Zacks Equity Research
Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.
Reasons to Add Allscripts (MDRX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?
by Zacks Equity Research
Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).
Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?
by Zacks Equity Research
Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Idexx (IDXX) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Analyst Reports for salesforce, General Motors & Block
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), General Motors Company (GM), and Block, Inc. (SQ).
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays
by Zacks Equity Research
IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.
Idexx Laboratories (IDXX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 13.17% and 2.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN
by Debanjana Dey
The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Analysts Estimate Idexx Laboratories (IDXX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP